LLY vs REGN Stock Comparison: AI Score, Valuation, Performance and Upside
Eli Lilly and Regeneron are both leading biopharmaceutical companies, but Eli Lilly's growth is currently driven primarily by its dominant position in the fast-growing GLP-1 obesity and diabetes drug market, while Regeneron's growth is anchored by Dupixent's continued label expansion in immunology, alongside a maturing ophthalmology franchise facing biosimilar competition.
Eli Lilly offers concentrated exposure to the large, rapidly growing GLP-1 obesity drug market at a premium valuation, while Regeneron offers a more diversified biotechnology platform anchored by Dupixent's growth, with a more moderate valuation but facing biosimilar pressure in its ophthalmology franchise. Consider whether you want concentrated GLP-1 exposure or Regeneron's more diversified biotech pipeline.
LLY holds the edge across 4 of 5 key metrics in this comparison. LLY has delivered stronger 1-year price return (+51.85% vs +35.19%), though REGN has the better forward P/E setup (13.10x vs 24.87x for LLY). LLY leads on both revenue growth (47.70%) and operating margin (54.22%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for LLY (+11.96%) than for REGN (+5.82%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want concentrated exposure to the rapidly growing GLP-1 obesity and diabetes drug market
- Believe manufacturing capacity expansion will continue unlocking Mounjaro and Zepbound demand
- Value a broad, diversified pipeline spanning oncology, immunology, and neuroscience beyond GLP-1
- Are comfortable paying a premium valuation for a dominant, fast-growing pharmaceutical leader
- Want exposure to Dupixent's continued growth and label expansion in immunology and dermatology
- Value Regeneron's proprietary antibody discovery platform as a differentiated drug development engine
- Prefer a more moderately valued biotechnology company over a premium-priced GLP-1 leader
- Are comfortable with Eylea franchise headwinds from biosimilar competition
| Metric | LLY | REGN |
|---|---|---|
| AI scorei | 75.8 | 43.7 |
| AI ranki | #21 | #860 |
| Latest closei | $1,136.11 | $774.11 |
| 1M returni | -3.73% | -3.66% |
| 6M returni | +22.12% | +1.98% |
| 1Y returni | +51.85% | +35.19% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | LLY | REGN |
|---|---|---|
| 1Y ago | $14.86K (+48.6%) started 2025-09-16 | $13.46K (+34.6%) started 2025-09-16 |
| 5Y ago | $53.18K (+431.8%) started 2021-09-17 | $11.92K (+19.2%) started 2021-09-17 |
| 10Y ago | $195.12K (+1851.2%) started 2016-09-19 | $19.29K (+92.9%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | LLY | REGN |
|---|---|---|
| Market capi | $1.05T | $81.77B |
| Trailing P/Ei | 39.36 | 19.65 |
| Forward P/Ei | 24.87 | 13.10 |
| Price/Salesi | 14.10 | 3.78 |
| EV/Revenuei | 13.72 | 4.76 |
| Analyst targeti | $1,315.04 | $840.43 |
| Target upsidei | +11.96% | +5.82% |
| Metric | LLY | REGN |
|---|---|---|
| Revenue growthi | 47.70% | 16.70% |
| Earnings growthi | 26.20% | -4.50% |
| EPS growthi | +26.20% | -4.50% |
| FCF margini | +13.89% | +19.73% |
| Operating margini | 54.22% | 33.11% |
| Profit margini | 33.53% | 27.87% |
| ROIC proxyi | 102.29% | 14.04% |
| Return on equityi | 102.29% | 14.04% |
| Dividend yieldi | 0.59% | 0.47% |
| Payout ratioi | 21.69% | 9.01% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 0.51 | 0.19 |
| Debt/equityi | 162.07 | 8.54 |
| Current ratioi | 1.35 | 3.33 |
| Quick ratioi | 0.68 | 2.63 |
Over the past year, LLY and REGN have moved weakly in the same direction (correlation of 0.36), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | LLY | REGN |
|---|---|---|---|
| 1Y | Growthi | +48.57% | +34.61% |
| CAGRi | +48.68% | +34.69% | |
| Volatilityi | 35.77% | 33.59% | |
| Sharpe ratioi | 1.16 | 0.92 | |
| Sortino ratioi | 1.96 | 1.43 | |
| Max drawdowni | 23.31% | 26.05% | |
| Current drawdowni | 11.26% | 9.15% | |
| Avg drawdowni | 6.51% | 8.17% | |
| Ulcer Indexi | 8.56% | 11.04% | |
| Max daily dropi | 7.79% | 9.82% | |
| Max wkly dropi | 8.60% | 12.87% | |
| 5Y | Growthi | +412.31% | +19.08% |
| CAGRi | +38.67% | +3.56% | |
| Volatilityi | 32.75% | 31.13% | |
| Sharpe ratioi | 1.03 | 0.12 | |
| Sortino ratioi | 1.59 | 0.18 | |
| Max drawdowni | 34.48% | 59.69% | |
| Current drawdowni | 11.26% | 35.41% | |
| Avg drawdowni | 7.38% | 20.18% | |
| Ulcer Indexi | 10.20% | 27.93% | |
| Max daily dropi | 14.14% | 19.01% | |
| Max wkly dropi | 17.93% | 20.21% | |
| 10Y | Growthi | +1564.19% | +92.70% |
| CAGRi | +32.50% | +6.79% | |
| Volatilityi | 30.55% | 32.14% | |
| Sharpe ratioi | 0.93 | 0.23 | |
| Sortino ratioi | 1.44 | 0.33 | |
| Max drawdowni | 34.48% | 59.69% | |
| Current drawdowni | 11.26% | 35.41% | |
| Avg drawdowni | 6.95% | 21.32% | |
| Ulcer Indexi | 9.34% | 26.89% | |
| Max daily dropi | 14.14% | 19.01% | |
| Max wkly dropi | 17.93% | 20.21% |
| Category | LLY | REGN |
|---|---|---|
| Company | Eli Lilly and Company | Regeneron Pharmaceuticals, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Biotechnology |
| Core business | A global pharmaceutical company with a leading position in GLP-1 diabetes and obesity drugs (Mounjaro, Zepbound), alongside a broad portfolio spanning oncology, immunology, and neuroscience. | A biotechnology company known for its antibody drug discovery platform, with Dupixent (immunology/dermatology) as its flagship product, alongside an ophthalmology franchise (Eylea) and a growing oncology pipeline. |
| Investor focus | GLP-1 obesity and diabetes drug revenue growth, manufacturing capacity expansion to meet demand, pipeline progress in oncology and Alzheimer's, and margin trends. | Dupixent revenue growth and label expansion, Eylea franchise competitive dynamics amid biosimilar competition, and pipeline diversification progress. |
- Leading position in the rapidly growing GLP-1 obesity and diabetes drug market with strong demand for Mounjaro and Zepbound
- Broad, diversified pipeline spanning oncology, immunology, and neuroscience beyond its GLP-1 franchise
- Strong pricing power and brand recognition supporting premium market positioning in key therapeutic areas
- Dupixent has become a major growth driver with continued label expansions across multiple immunology and dermatology conditions
- Proprietary antibody discovery platform (VelocImmune) supports a differentiated, self-sustaining drug development engine
- Diversified revenue across immunology, ophthalmology, and an expanding oncology pipeline
- Manufacturing capacity constraints have historically limited the ability to fully meet GLP-1 drug demand
- Increasing competition in the obesity drug market from other pharmaceutical companies developing rival GLP-1 treatments
- Premium valuation leaves less room for pipeline or commercial execution disappointments
- Eylea franchise faces increasing competitive and biosimilar pressure in the ophthalmology market
- Smaller scale and narrower near-term commercial focus than Eli Lilly's broader, GLP-1-driven growth story
- Pipeline and regulatory execution risk inherent to biotechnology drug development
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.